Egalet Corporation (NASDAQ:EGLT) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On January7, 2019, Robert Radie, President and Chief Executive Officer of the Company, will be using the presentation furnished as Exhibit99.1 hereto at the J.P. Morgan Healthcare Conference.
The information set forth this Item 7.01 (including Exhibit99.1) is being furnished to Item 7.01 and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 — Financial Statements and Exhibits
(d)Exhibits
|
ExhibitNumber |
Description |
|
99.1 |
Egalet Corporation Investor Presentation. |
Egalet Corp Exhibit
EX-99.1 2 a19-2005_1ex99d1.htm EX-99.1 Exhibit 99.1 Commercial Company with a Focus on Pain January 2019 © Copyright 2019. Egalet Corporation 1 Forward Looking Statements Statements included in this presentation that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations,…
To view the full exhibit click here
About Egalet Corporation (NASDAQ:EGLT)
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
